Alprazolam Tablets
CGMP Deviations: Potential risk of Cross Contamination
Recalls of antidepressants, anti-anxiety and related psychiatric medications.
224 recalls in this category, newest first.
CGMP Deviations: Potential risk of Cross Contamination
CGMP Deviations: Potential risk of Cross Contamination
CGMP Deviations: Potential risk of Cross Contamination
Failed Impurities/Degradation Specifications
Failed Tablet/Capsule Specification; oversized tablet found in a bottle
Presence Of Foreign Substance: Customer complaint for the presence of dark, gritty substance found within the bottle which was determined to be activated carbon from the desiccant canister inside the bottle.
Presence Of Foreign Substance: Customer complaint for the presence of dark, gritty substance found within the bottle which was determined to be activated carbon from the desiccant canister inside the bottle.
Failed Dissolution Specifications: low out of specification results for dissolution.
Failed Dissolution Specifications: low out-of-specification dissolution test results observed.
CGMP Deviations: The Recall is due to the potential cross-contamination at the contract manufacturer (Ultra Tab Laboratories Inc.)
CGMP Deviations: The Recall is due to the potential cross-contamination at the contract manufacturer (Ultra Tab Laboratories Inc.)
CGMP Deviation: Potential cross-contamination with other drug substance during the manufacturing process.
CGMP deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Presence of Forein Tablets/Capsules; Venlafaxine Tablets, USP 37.5 mg found in bottles labeled as Venlafaxine Tablets, USP, 50 mg
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint
Cross contamination with other products - OOS discovered during routine stability testing for highest unknown impurity later identified as clozapine
Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.
Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.
Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.